Jaguar Health (JAGX) Amortization of Deferred Charges (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Amortization of Deferred Charges of $47000.0 for Q1 2026, down 29.85% year-over-year from $67000.0 in Q1 2025, and up 167.14% quarter-over-quarter from -$70000.0 in Q4 2025.
Jaguar Health (JAGX) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Amortization of Deferred Charges for 12 consecutive years, with $47000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 29.85% year-over-year to $47000.0; the TTM figure through Mar 2026 stood at $133000.0 (down 42.67% YoY), while the FY2025 annual figure was $153000.0, down 44.16% from the prior year.
- Amortization of Deferred Charges rose to $47000.0 in Q1 2026 per JAGX's latest filing, from -$70000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $3.4 million in Q1 2022 and bottomed at -$8.5 million in Q4 2022.
- Historically, Amortization of Deferred Charges has averaged $68235.3 across 5 years, with a median of $89000.0 in 2023.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 205.95% in 2022 and fell as far as 265.43% in 2022.
- Jaguar Health's Amortization of Deferred Charges stood at -$8.5 million in 2022, then soared by 101.05% to $89000.0 in 2023, then plunged by 177.53% to -$69000.0 in 2024, then dropped by 1.45% to -$70000.0 in 2025, then soared by 167.14% to $47000.0 in 2026.
- Business Quant data shows JAGX's Amortization of Deferred Charges at $47000.0 in Q1 2026, -$70000.0 in Q4 2025, and $78000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,000.00 |
| Mar 31, 2026 | 47,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Sep 30, 2024 | 122,000.00 |
| Sep 30, 2024 | 122,000.00 |
| Jun 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 112,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Dec 31, 2023 | 89,000.00 |